A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.
COVID-19
adjuvant
antigen-sparing
egg-based vaccine
hamster model
mouse-adapted SARS-CoV-2
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
05
11
2020
revised:
12
12
2020
accepted:
15
12
2020
entrez:
22
12
2020
pubmed:
23
12
2020
medline:
23
12
2020
Statut:
epublish
Résumé
A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent coronavirus disease 2019 (COVID-19) vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.
Identifiants
pubmed: 33348607
pii: vaccines8040771
doi: 10.3390/vaccines8040771
pmc: PMC7766959
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00051
Pays : United States
Organisme : Open Philanthropy Project
ID : #2020-215611
Organisme : JPB foundation
ID : philanthropic donation
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI149644
Pays : United States
Organisme : NIH U01
ID : AI149644
Commentaires et corrections
Type : UpdateOf
Références
J Pediatric Infect Dis Soc. 2015 Sep;4(3):242-51
pubmed: 26336604
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32554612
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Mol Pharm. 2012 Feb 6;9(2):261-8
pubmed: 22142394
J Integr Agric. 2017 Oct;16(10):2264-2273
pubmed: 32288953
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
Int J Pharm. 2017 Oct 30;532(1):37-46
pubmed: 28866132
Methods Mol Biol. 2020;2058:133-154
pubmed: 31486036
mBio. 2020 Apr 7;11(2):
pubmed: 32265331
J Immunol. 2019 Jun 15;202(12):3524-3536
pubmed: 31053626
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9788-93
pubmed: 17535926
EBioMedicine. 2020 Dec;62:103132
pubmed: 33232870
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
J Biomed Biotechnol. 2010;2010:586363
pubmed: 20625497
Lancet Infect Dis. 2020 Jul;20(7):827-838
pubmed: 32325037
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Vaccine. 2017 Apr 4;35(15):1865-1872
pubmed: 28302407
Vaccine. 2008 Apr 16;26(17):2164-74
pubmed: 18346823
J Pediatric Infect Dis Soc. 2016 Jun;5(2):170-9
pubmed: 26407273